Thanks, Jack, for us you call first XXXX. everyone. hello and Thank for today joining of our earnings
highlight regular on will report was in, dive I'll like where to we portion following be forward, today, conference calls of note holding look remarks this to our significant we in Q&A to highlight for I'd I'd progress. while going like the prepared addition discuss of Before team presenting cadence also anticipate increase that be to we'll quarterly our Zymeworks shareholders that periodic entire the engagement available the calls and executive call. matters, earnings we as and
As to quickly always, tuning those opportunities in. public look I to items. we our for and like on forward two the touch shareholders dialogue would with
are management that organization of to across pipeline continuing from through around expanding treat will to and a and candidates to highlight with early the our difference overarching are building biopharmaceutical we product a patients clinical discovery an corporate world we already well achieve. goal for leading cancers. corporate the a of late-stage with that hard company research make restructuring With I to development team a exciting significant hope focus want with as we First, the seeking the underway, objectives larger align increase
focused, is look cost achieving our a has focus towards key that adjustments organization. team truly stated corporate through relevant upon goal, deliver next to we continue generation that novel we make can platforms a Zymeworks value as objectives. effective a therapeutics objectives to towards and make progress While technology work build our some This that clinically significant more drug, we internal can as efficient and execute and
call have I like President would may today's you the been and to start Officer. Chris announcement, seen Senior immediately as Chief Astle, earnings congratulating promoted Financial PhD by Vice effective Second, to in who has
pass held continue remain since I've and As look capacity. role important along Operating I current finance his CFO, with of the one as Chris my work him forward the has in new Officer. I in that will leader been position an Chief in I XXXX, to team, to
doubt no finance fullest, and of accounting results, clinical of This deep our XX, our right results the priorities. some to importance corporate of into catalysts. previously background like overview the and to role. followed clinical general welcome company, stage With on and we discipline that, upcoming and I Chris financial lastly, to biotech Given afternoon, utilize would of our this year financial I every jump strategic an new financial will programs for reported December update Zymeworks XXXX. by its And announced quarter Chris' a ended a into discussion
decrease year in expansion various well partners support payments This the under the from non-recurring from arrangements. fees, the to payments, a is in by technology, our for XX, X X and related expenses and licensing development, higher General and partially trials Research milestone as ended XXXX year was licensing million and X.X million increases to the million in and collaboration BeiGene from development two expense ended XX, milestones, This the year for for in for to million benefits of compared headcount ended drug to million clinical was from XXX.X expenses XX, Janssen XXX.X for were additional year revenue December December was due our arrangements. million increase from year-over-year and salary and to incorporates reported, December Revenue million activities. our the ZymeLink manufacturing a recovery from compensation XXXX. expense XXXX. development sharing million was which primarily Therapeutics administrative XX, development for upfront million XXXX offset which million XX.X million XXXX with XBXXX, received research for classified XX liability ended of for XX.X received from administrative certain of XX.X from a compared primarily XXXX, X.X a the revenue cost and included XXXX offset revenue decrease timing revenue ICON-X, compared historical million XX, or XX, formerly stock-based research As XX.X conjunction to December X related revaluation In compared year mark-to-market XX.X XXXX. for classified from recovery non-cash expense development year of as for their expense in to equity million awards, awards. the Iconic ended December an general and non-cash ended December by milestone, ADC included
and benefits XXXX. on XXXX. non-GAAP refund XXXX we fees, a X.X The professional by increased from recognized million headcount and expense, to compensation by primarily tax state or XX% general administrative was basis higher stock-based partially in offset additional and expenses increase expense due in sales salary Excluding compared to U.S.
for to of million income, revenue was net and loss the was general Zymeworks lower in increases The development XXXX million XX, expense. and in year XXX.X net by expenses in primarily As compared loss to partially interest and administrative December and XXXX. in research offset due XXX.X increase in decrease
completed of but public excluding of period. Our cash, investments, cash recently proceeds short-term and our the end from the cash the million equivalents reporting at offering, consisting was XXX.X resources
and quarterly I'll encourage our and non-GAAP of filings www.zymeworks.com. you financials, financial additional Web on a into some release a GAAP our reconciliation available highlights. color other earnings I description clinical With our and of to review for on site For results that, to measures at SEC our non-GAAP move
zanidatamab biparatopic novel update HERX-targeting Let the and key our lead antibody. path. product we This as candidate, working an me milestones start commercialization a its be that zanidatamab, will determine be of towards to data crucial and readouts will on by help year will providing commercial multiple development
cancer, for metastatic completing our enrollment zanidatamab HERIZON-BTC-XX trial, zanidatamab treated be will in advanced milestone previously XXXX biliary for a first HERX-amplified as or BTC. or upcoming first pivotal monotherapy in evaluating tract The
with patients for this determined We of an by in expect middle This China. independent subjects XX rate two-thirds endpoint recruited review of central of by at population as year. primary complete a this study objective based the outside least study being evaluable to is response of on in pivotal countries patient enrollment
or received Orphan adenocarcinoma, also BTC the as for and zanidatamab BTC a gene-amplified short, States, GEA previously designation and BTC previously Drug and designations, HERX has for HERX-positive for in one standard of reminder, the Therapy combination FDA Zanidatamab chemotherapy. care for Breakthrough cancer for patients European As well Track first-line BTC recurrent of been the designation Union. gastroesophageal in treatment and United another by Fast in for or treated has two treated as with the gastric granted with GEA
chemotherapy with patients enrollment BeiGene's advanced with we global pivotal combination or with pivotal In presented in at anti-PD-X GEA. with Medical randomized, is Society HERIZON-GEA-XX, Congress. metastatic and that zanidatamab first-line the a promising Oncology and year in study, second addition, for in evaluating we GEA without last or zanidatamab for study This by study with Annual tislelizumab which HERX-positive first-line results chemotherapy zanidatamab October are continuing European supported is for of locally combination
have November's Committee, an trial, issues GEA, enrollment, two will with chemotherapy. of the is to from on to tislelizumab As plus to standard patients Drugs label, conference we continuing of And through of standard zanidatamab one, this of call, chemotherapy currently be trial as and that webcast approximately to enrolled strongly pivotal to the arms, ODAC, anticipated, is in chemotherapy with Advisory global current launch population trastuzumab care its plus the one global XXXX. zanidatamab by XXX extensive of experimental HERIZON-GEA-XX. diverse to randomized versus completed total bearing in sites end care to in standard zanidatamab It of Oncologic raised patient open or plus compare XX or one the countries. that believed of that plus The we detail trial nature HERIZON-GEA-XX due and to prior important consultation one the which we care first-line XXX launch, note by in three-arm a spoke is unrelated this global expect will little be the FDA
event for that reported discuss investor highlight to meeting. our also of the of we would while zanidatamab like the of Asia to that I program of significance and to two aware been we development have of an look to GEA the the data forward reporting at in upcoming important ASCO holding the data June annual submitted generated will the with studies supply by to data do presentation for are impacts at our following Wushi ongoing to HERX-positive product not any list meeting for U.S. pivotal zanidatamab, year. the this important of anticipate acceptance impacts In partner, or placed abstracts, on Zymeworks potential Department the non-verified in continued these and certain portfolio. being to has supply BeiGene, chain Commerce, breast on addition chains conjunction cancer and progress we in we that our status Pacific Subject
constraints placed to including the capital of the pertain Specifically, to or U.S. or jurisdictions, do EU. and manufacturing purchases not not limit that any product do impact our equipment export upon Wushi operations import other
provide to like antibody-drug a I'd conjugate. brief ZWXX, update Finally, biparatopic our on clinical-stage
X evaluating solid HERX-expressing We with patients have study monotherapy an tumors. open ZWXX in clinical ongoing trial in an label, as Phase
completed we Currently, tolerable as work we enrollment been have three-week We we dose XXXX. to every have observed recommended we patients no initiated in a weekly which dose continue expansion any continue cohort, in to parallel, toxicities dose, date. maximum establishing of regimen. evaluate in a X towards and to XX reached, Phase not And has the limiting dosing
half medical data presented meeting have major forward for and we at inform the time. path clinical this expect in updates to year. to of ZWXX presented at The continue previously data our will providing we development ZWXX, further to that look we As a second guided, the be
on our product clinical-stage our focus assets, generating R&D are teams utilizing therapeutic to our addition candidates continuing In platforms. to
INDs provide at to team. goal, be foreign R&D R&D to the of have our to an current on Our for least We by this previously two highlighted, as is in event fourth of equivalents our therapeutics update hosted the novel at end an filed program XXXX. and by and or hope quarter their work preclinical able year
clinical partnerships and On front, we the creation non-core we for value our aggressively as and of programs. focused monetization collaborations our collaboration R&D pursue acutely assets and partnership remain on and
into progress including As have look update forward well these earlier potential breast multiple updates a in zanidatamab, like ability make funding expanding tandem, and CDXX future opportunities partnership as programs, and partnership previously product to providing colorectal, cancers strategy make We as property will SARS-CoV-X. we zanidatamab's announced physicians. it toxicity continue R&D and ACEX to pursue combined program and believe and novel in patients indications decoy additional we in lines potential appealing out-licensing, January, lung and and to also as the candidates particularly opportunities zanidatamab other into to our targeting monetize targeting where In we opportunities. MET, non-core look we as stage intellectual early of we for IL-XX, towards to therapy profile and
Moving of on, have for position, made including cash on our the to towards improving and objectives, now recent years. key progress want burn coming I we touch runway cash financial our one
As is reduction our leadership on we well followed targeting The XX, at previously by workforce of of completed team, a reduction mentioned, immediate January streamlining of overall in a senior underway. the the headcount the end of an employee headcount year. by least XX% reduction
financials. of reduction to While XX% of targeted in the the expect exceed related will reflected we that cost by to reduction workforce be we anticipate XXXX X, in our majority headcount March our the savings
rapidly of gross an rate million. the current shifting background environment, new who Despite both a events, underwritten global offering biotech participated we recently from where of received macroeconomic proceeds the very we we were pleased XXX sentiments in financing. with support headwinds and addition, global from this and shown In changing public closed investors
our the reduction headcount in current reported an million, anticipate we this second at cash of from and R&D into provide at our of our of financing, that With XXXX. with runway XXX.X half us Looking G&A the combined December spend, XXXX XX, extension the cash proceeds runway. including reductions, will balance
we on of executing enhancing a presenting development be path collaborations, include least zanidatamab, position technology and pivotal asset to reiterate operating clinical for component our the Additionally, sources recruitment well financial to To of of and two identifying continuing January. our successfully our non-core clear and rebuilding of and collaborations restructuring, ZWXX. through monetization in continuing meeting I HERIZON-GEA-XX, executing executing those realizing now importance for path our XXXX provided novel updates. HERIZON-BTC-XX believe and take a and the partnerships of through and advance we studies priorities mentioned order runway full partnerships, and strategies our efficiencies a overall like pipeline, beyond data early Selecting end our by success as future and for result support to a and to by R&D and support we gained moment update priorities as potentially collaborations, the end the will in, other the zanidatamab, strategic XXXX, strategic monetization advancing company. in of therapeutics core core funding. the two and able partnership identifying and that platforms to of at and improve through in development clinical major in stage moreover, guidance recently and remind on to our our the aggressively our a value Each these of listening upon further and key medical clinical of of new finalizing as non-dilutive at development and would strategies, key future previously these clinical is commercialization pursuing in
focus reset maximizing the continue Zymeworks on value remains outcomes, we company shareholder ambitious and positioned execute our on to both to well plan. patient and incredibly As
pivotal exhibited a have clinically meaningful and that tolerated. therapeutic data stage is has well We
completing forward Chair operator We novel have ongoing I to Medical Executive look have And are clinical I team question-and-answer over upcoming And Chief Officer, to truly Galbraith; where as Dr. data Chris the drug Officer, multiple today trials more to to towards of indications updates capable world clearly is these our platforms and for newly answer our Officer, catalysts and priorities. than our progress With class creating and Zymeworks. a session. begin candidates. and questions now competitive. that, we R&D and we Josephson; we Kenneth ever, providing will Chief call Financial turn promoted I Chief excited Neil of With Astle. the the remain future the me key
